Neuronetics Gelecekteki Büyüme
Future kriter kontrolleri 1/6
Neuronetics is forecast to grow earnings and revenue by 37.8% and 14.2% per annum respectively while EPS is expected to grow by 43.2% per annum.
Anahtar bilgiler
37.8%
Kazanç büyüme oranı
43.2%
EPS büyüme oranı
| Medical Equipment kazanç büyümesi | 17.4% |
| Gelir büyüme oranı | 14.2% |
| Gelecekteki özkaynak getirisi | n/a |
| Analist kapsamı | Low |
| Son güncelleme | 22 Oct 2024 |
Gelecekteki son büyüme güncellemeleri
Recent updates
Investors Give Neuronetics, Inc. (NASDAQ:STIM) Shares A 60% Hiding
Aug 13
Here's Why Shareholders May Want To Be Cautious With Increasing Neuronetics, Inc.'s (NASDAQ:STIM) CEO Pay Packet
May 24The Neuronetics, Inc. (NASDAQ:STIM) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 09Neuronetics: Reality Set In
May 09Market Cool On Neuronetics, Inc.'s (NASDAQ:STIM) Revenues Pushing Shares 36% Lower
May 08Neuronetics (NASDAQ:STIM) Has Debt But No Earnings; Should You Worry?
May 01Even With A 26% Surge, Cautious Investors Are Not Rewarding Neuronetics, Inc.'s (NASDAQ:STIM) Performance Completely
Mar 17Neuronetics: Modest Improvements Are Not Enough
Jan 30Neuronetics, Inc. (NASDAQ:STIM) Soars 61% But It's A Story Of Risk Vs Reward
Dec 19Neuronetics, Inc.'s (NASDAQ:STIM) Shares Not Telling The Full Story
Jun 21Does Neuronetics (NASDAQ:STIM) Have A Healthy Balance Sheet?
May 10Neuronetics: Growth To Capture, But Fairly Priced
Sep 06Is Neuronetics (NASDAQ:STIM) Using Debt Sensibly?
Sep 06Neuronetics gets FDA nod for its D-Tect accessory product for use to treat depression
Aug 29Neuronetics GAAP EPS of -$0.39 beats by $0.02, revenue of $16.3M beats by $0.84M , revises FY guidance
Aug 02Neuronetics stock soars 30% as FDA clears NeuroStar system for anxious depression
Jul 19Is Neuronetics (NASDAQ:STIM) A Risky Investment?
Jun 08Kazanç ve Gelir Büyüme Tahminleri
| Tarih | Gelir | Kazançlar | Serbest Nakit Akışı | Faaliyetlerden Nakit | Avg. Analist Sayısı |
|---|---|---|---|---|---|
| 12/31/2026 | 100 | -14 | N/A | N/A | 2 |
| 12/31/2025 | 87 | -20 | N/A | N/A | 4 |
| 12/31/2024 | 78 | -27 | N/A | N/A | 4 |
| 6/30/2024 | 72 | -32 | -27 | -25 | N/A |
| 3/31/2024 | 73 | -28 | -31 | -29 | N/A |
| 12/31/2023 | 71 | -30 | -34 | -32 | N/A |
| 9/30/2023 | 69 | -33 | -39 | -37 | N/A |
| 6/30/2023 | 68 | -31 | -36 | -34 | N/A |
| 3/31/2023 | 67 | -37 | -36 | -34 | N/A |
| 12/31/2022 | 65 | -37 | -34 | -31 | N/A |
| 9/30/2022 | 62 | -37 | -36 | -32 | N/A |
| 6/30/2022 | 59 | -37 | -37 | -34 | N/A |
| 3/31/2022 | 57 | -34 | -34 | -31 | N/A |
| 12/31/2021 | 55 | -31 | -30 | -28 | N/A |
| 9/30/2021 | 56 | -27 | -27 | -25 | N/A |
| 6/30/2021 | 55 | -22 | -22 | -20 | N/A |
| 3/31/2021 | 50 | -23 | -25 | -24 | N/A |
| 12/31/2020 | 49 | -27 | -29 | -28 | N/A |
| 9/30/2020 | 51 | -31 | -34 | -33 | N/A |
| 6/30/2020 | 55 | -35 | -38 | -37 | N/A |
| 3/31/2020 | 61 | -34 | -35 | -35 | N/A |
| 12/31/2019 | 63 | -29 | -31 | -30 | N/A |
| 9/30/2019 | 61 | -28 | -27 | -26 | N/A |
| 6/30/2019 | 59 | -26 | -25 | -24 | N/A |
| 3/31/2019 | 55 | -26 | -23 | -22 | N/A |
| 12/31/2018 | 53 | -24 | -22 | -21 | N/A |
| 9/30/2018 | 49 | -23 | -19 | -18 | N/A |
| 6/30/2018 | 46 | -22 | -16 | -15 | N/A |
| 3/31/2018 | 43 | -17 | N/A | -13 | N/A |
| 12/31/2017 | 40 | -16 | N/A | -11 | N/A |
| 12/31/2016 | 34 | -11 | N/A | -9 | N/A |
Analist Gelecek Büyüme Tahminleri
Kazançlar ve Tasarruf Oranları: STIM is forecast to remain unprofitable over the next 3 years.
Kazançlar ve Piyasa: STIM is forecast to remain unprofitable over the next 3 years.
Yüksek Büyüme Kazançları: STIM is forecast to remain unprofitable over the next 3 years.
Gelir ve Pazar: STIM's revenue (14.2% per year) is forecast to grow faster than the US market (8.9% per year).
Yüksek Büyüme Geliri: STIM's revenue (14.2% per year) is forecast to grow slower than 20% per year.
Hisse Başına Kazanç Büyüme Tahminleri
Gelecekteki Özkaynak Getirisi
Gelecekteki ROE: Insufficient data to determine if STIM's Return on Equity is forecast to be high in 3 years time